Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.

Official Title

A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib

Keywords

Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Pirtobrutinib, JZ01 Pirtobrutinib

Eligibility

You can join if…

Open to people ages 18 years and up

  • Are participating in an eligible Lilly sponsored clinical study evaluating pirtobrutinib.

You CAN'T join if...

  • Are pregnant, or intend to become pregnant during the study, or within 30 days of last dose of study treatment or to breastfeed during the study or within 1 week of the last dose of study treatment.

Locations

  • University of California Medical Center
    San Francisco California 94143-2204 United States
  • Swedish Cancer Institute
    Seattle Washington 98104-3588 United States

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
ID
NCT06876649
Phase
Phase 4 research study
Study Type
Interventional
Participants
Expecting 279 study participants
Last Updated